2019;**140**(22):1834-1850. DOI: 10.1161/ CIRCULATIONAHA.119.040267

[11] Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study ofsystematic screening (targeted and total population screening) versus routinepractice for the detection of atrial fibrillation in people aged 65 and over TheSAFE study. Health Technology Assessment. 2005;**9**:1-74

[12] Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratificationfor predicting Stroke and thromboembolism in atrial fibrillation using anovel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;**137**:263-272

[13] Holmes DR, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin forStroke prevention in atrial fibrillation: A patient-level meta-analysis. Journal of American College of Cardiology. 2015;**65**:2614-2623

[14] Boersma LV, Ince H, Kische S, et al. EWOLUTION Investigators. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017 Sep;**14**(9):1302-1308

[15] Tsai YC, Phan K,

Munkholm-Larsen S, et al. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: A meta-analysis. European Journal of Cardio-Thoracic Surgery. 2015;**47**(5):847-854. DOI: 10.1093/ejcts/ ezu291

[16] Tilz RR, Potpara T, Chen J, et al. Left atrial appendage occluder implantation in Europe: Indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. Europace. 2017;**19**(10):1737-1742. DOI: 10.1093/ europace/eux254

[17] Groenveld HF, Crijns HJ, Van den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. Journal of the American College of Cardiology. 2011;**58**(17):1795-1803. DOI: 10.1016/j.jacc.2011.06.055

[18] Lim KT, Davis MJ, Powell A, et al. Ablate and pace strategy for atrial fibrillation: Long-term outcome of AIRCRAFT trial. Europace. 2007;**9**(7):498-505. DOI: 10.1093/ europace/eum091

[19] Wang RX, Lee HC, Hodge DO, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm. 2013;**10**(5):696-701. DOI: 10.1016/j.hrthm.2013.01.021

[20] Huang W, Su L, Wu S, et al. Benefits of Permanent his bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. Journal of the American Heart Association 2017 Apr 1;**6**(4):e005309

[21] Bunch TJ, May HT, Bair TL, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm. 2013;**10**(9):1257-1262. DOI: 10.1016/j.hrthm.2013.05.013

[22] Teh AW, Kistler PM, Lee G, Medi C, et al. Long-term effects of catheter ablation for lone atrial fibrillation:

*Advances in the Nonpharmacological Treatment of Atrial Fibrillation DOI: http://dx.doi.org/10.5772/intechopen.105138*

Progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm. 2012;**9**(4):473- 480. DOI: 10.1016/j.hrthm.2011.11.013

[23] Kirchhof P, Mönnig G, Wasmer K, et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). European Heart Journal. 2005;**26**(13):1292-1297. DOI: 10.1093/ eurheartj/ehi160

[24] Soulat-Dufour L, Lang S, Addetia K, et al. Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regurgitation in patients with atrial fibrillation. Journal of the American College of Cardiology. 2022;**79**(10):951- 961. DOI: 10.1016/j.jacc.2021.12.029

[25] Inácio JF et al. Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network metaanalysis. Resuscitation. 2016;**100**:66-75. DOI: 10.1016/j.resuscitation.2015.12.009

[26] Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart. 2015;**101**(19):1526-1530. DOI: 10.1136/ heartjnl-2015-307656

[27] Toufan M, Kazemi B, Molazadeh N. The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. Journal of Cardiovascular and Thoracic Research. 2017;**9**(1):54-59. DOI: 10.15171/ jcvtr.2017.08

[28] Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study. Journal of the American Medical Association. 2014;**311**(5):498-506. DOI: 10.1001/jama.2014.3

[29] Li Z, Wang S, Hidru TH, et al. Fibrillation duration and early recurrence are reliable predictors of late recurrence after radiofrequency catheter ablation. Frontiers in Cardiovascular Medicine. 2022;**9**:864417. DOI: 10.3389/ fcvm.2022.864417

[30] Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. Journal of the American College of Cardiology. 2014;**64**(21):2222-2231. DOI: 10.1016/j. jacc.2014.09.028

[31] Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, controlled trial of the safety and effectiveness of a contact forcesensing irrigated catheter for ablation of paroxysmal atrial fibrillation: Results of the tacticath contact force ablation catheter study for atrial fibrillation (TOCCASTAR) study. Circulation. 2015;**132**(10):907-915. DOI: 10.1161/ CIRCULATIONAHA.114.014092

[32] Hindricks G, Sepehri Shamloo A, Lenarczyk R, et al. Catheter ablation of atrial fibrillation: Current status, techniques, outcomes and challenges. Kardiologia Polska. 2018;**76**(12):1680- 1686. DOI: 10.5603/KP.a2018.0216

[33] Imberti JF, Ding WY, Kotalczyk A, et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: A systematic review and meta-analysis. Heart. 2021;**107**(20):1630-1636. DOI: 10.1136/ heartjnl-2021-319496

[34] Kircher S, Arya A, Altmann D, Rolf S, et al. Individually tailored vs. standardized substrate modification duringradiofrequency catheter ablation for atrial fibrillation: A randomized study. Europace. 2018;**20**:1766-1775

[35] Arbelo E, Brugada J, Blomström-Lundqvist C, et al. On the behalf of the ESC-EHRA Atrial Fibrillation Ablation Long-term Registry Investigators. Contemporary management of patients undergoing atrial fibrillation ablation: In-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal. 2017;**38**(17):1303-1316. DOI: 10.1093/eurheartj/ehw564

[36] Bagge L, Probst J, Jensen SM, et al. Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: A substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Europace. 2018;**20**(FI\_3):f343-f350. DOI: 10.1093/europace/eux253

[37] Kim HJ, Kim JS, Kim TS. Epicardial thoracoscopic ablation versus endocardial catheter ablation for management of atrial fibrillation: A systematic review and meta-analysis. Interactive Cardiovascular and Thoracic Surgery. 2016;**22**:729-737

[38] Gammie JS, Haddad M, Milford-Beland S, et al. Atrial fibrillation correction surgery: Lessons from the Society of Thoracic Surgeons National Cardiac Database. The Annals of Thoracic Surgery. 2008;**85**:909-914

[39] van der Heijden CAJ, Vroomen M, Luermans JG, et al. Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: A systematic review and meta-analysis†. European Journal of Cardio-Thoracic Surgery. 2019;**56**(3):433-443. DOI: 10.1093/ejcts/ ezy475
